First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group study

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 207-214

  Kroep, J R ^a   Ouali, M ^b   Gelderblom, H ^a   Le Cesne, A ^c   Dekker, T J A ^a   van Glabbeke, M ^b   Hogendoorn, P C W ^a   Hohenberger, P ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adriamycin; Chemotherapy; Ifosfamide; Malignant peripheral nerve sheath tumor; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE SHEATH TUMOR; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL NERVE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 78650413391     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq338     Document Type: Article

References (33)

1. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. St Louis, MO: Mosby, Inc. 2007.
2. Evans DG, Baser ME, McGaughran J et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-314.
3. Ducatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57: 2006-2021.
4. Carli M, Ferrari A, Mattke A et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23: 8422-8430.
5. Anghileri M, Miceli R, Fiore M et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107: 1065-1074.
6. Wong WW, Hirose T, Scheithauer BW et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998; 42: 351-360.
7. Casali PG, Jost L, Sleijfer S et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii89-ii93.
8. van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
9. Koea JB, Leung D, Lewis JJ et al. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 2003; 10: 432-440.
10. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland 1979.
11. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 2001; 37: 1-3.
12. Graadt van Roggen JF, Bovee JV, Morreau J et al. Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours. J Clin Pathol 1999; 52: 481-489.
13. Hogendoorn PC, Collin F, Daugaard S et al. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 2004; 40: 1644-1654.
14. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 2433-2436.
15. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
16. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
17. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009; 27: 3126-3132.
18. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
19. Ferrari A, Casanova M, Collini P et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005; 23: 4021-4030.
20. Masui F, Yokoyama R, Soshi S et al. A malignant peripheral nerve-sheath tumour responding to chemotherapy. J Bone Joint Surg Br 2004; 86: 113-115.
21. Brooks JS, Freeman M, Enterline HT. Malignant "Triton" tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer 1985; 55: 2543-2549.
22. Steins MB, Serve H, Zuhlsdorf M et al. Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy. Oncol Rep 2002; 9: 627-630.
23. Kinebuchi Y, Noguchi W, Igawa Y et al. Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol 2005; 10: 353-356.
24. Maurel J, Lopez-Pousa A, de Las PR et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 2009; 27: 1893-1898.
25. Basu TN, Gutmann DH, Fletcher JA et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-715.
26. Tawbi H, Thomas D, Lucas DR et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 2008; 13: 459-466.
27. Albritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2006; 24(18S): Abstr 9518.
28. Angelov L, Salhia B, Roncari L et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 1999; 59: 5536-5541.
29. Cichowski K, Shih TS, Schmitt E et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176.
30. Vogel KS, Klesse LJ, Velasco-Miguel S et al. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286: 2176-2179.
31. MacInnes AW, Amsterdam A, Whittaker CA et al. Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A 2008; 105: 10408-10413.
32. Berghmans S, Murphey RD, Wienholds E et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A 2005; 102: 407-412.
33. McCarron KF, Goldblum JR. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases. Mod Pathol 1998; 11: 612-617.